Cd3 pc7

Manufactured by BD

The CD3-PC7 is a fluorescence-based flow cytometry reagent produced by BD Biosciences. It is used for the detection and analysis of CD3-positive T cells in biological samples. The reagent contains a fluorochrome-conjugated antibody that specifically binds to the CD3 surface antigen, allowing for the identification and quantification of T cells within a sample.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using cd3 pc7

Comprehensive NK Cell Profiling in Melanoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

NK cell phenotype of melanoma patients enrolled in the trial was examined using fluorochrome-conjugated antibodies against the following cell-surface markers: CD56-FITC, CD3-PC7, CD16-APC, CD69-BV421, NKp30-BV711, CXCR3-BV421, CCR3-BV510 (BD Biosciences; San Diego, CA), NKp44-PerCP eFluor 710 (eBioscience; San Diego, CA), CXCR1-PE (R&D Systems; Minneapolis, MN), CCR7-BV711 (BioLegend; San Diego, CA), and matching IgG isotype controls from the same vendors. The immune checkpoint and NK cell activation receptor panel included the following markers: Zombie NIR Fixable Viability Dye (BioLegend; San Diego, CA), CD3-PE-Vio770 (Miltenyi Biotec; San Diego, CA), ANK-1-PE (Santa Cruz Biotechnology; Dallas, TX), TIGIT-PerCP eFluor 710 (eBioscience), CD45-BUV395, CD56-BV510, CD16-BUV737, NKG2D-APC, NKp46-BV711, CD69-BV421, and PD-1-BV650 (BD Biosciences).

Vujanovic L., Chuckran C., Lin Y., Ding F., Sander C.A., Santos P.M., Lohr J., Mashadi-Hossein A., Warren S., White A., Huang A., Kirkwood J.M, & Butterfield L.H. (2019). CD56dim CD16− Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α. Frontiers in Immunology, 10, 14.

+ Open protocol

+ Expand

Multimerization of pMHC Monomers for TCR Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

pMHC‐monomers were generated as previously described.⁶⁰ All biotinylated pMHC‐monomers were multimerised by incubation of 4 µg biotinylated pMHC monomer with 1 µg streptavidin‐BV421 (BioLegend; San Diego, California) or streptavidin‐PE (BioLegend) in a total volume of 100 µL FACS buffer per 1 x 10⁷ cells. The following antibodies were used: anti‐human TCR α/β PE (BioLegend), CD3 PC7 (BD Biosciences; San Jose, California), CD8α PE (Invitrogen, Thermo Fisher Scientific), CD8β PC5.5 (Beckman Coulter; Brea, California), CD45 PerCP (Thermo Fisher Scientific), CD45 ECD (Beckman Coulter), CD45 PC7 (eBioscience, Thermo Fisher Scientific) and anti‐mTRBC APC (Biolegend). Live/dead discrimination was performed with propidium iodide (Invitrogen).

Müller T.R., Schuler C., Hammel M., Köhler A., Jutz S., Leitner J., Schober K., Busch D.H, & Steinberger P. (2020). A T‐cell reporter platform for high‐throughput and reliable investigation of TCR function and biology. Clinical & Translational Immunology, 9(11), e1216.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!